VALIDOGENRecombinant protein production in Pichia typically relies on AOX1 promoter-driven expression using methanol for induction. However, some companies avoid methanol due to safety concerns or operational demands. VALIDOGEN’s unique AOX1 promoter variants enable methanol-free protein production at high space-time yields, offering advantages beyond safety. Latest case studies underscore the strength of this technology.
Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide.
Image by freepikPurespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
Eppendorf SE Bioprocess CenterEfficiency and flexibility are key factors to stay competitive in the bioprocess field. With this aim in mind, the SciVario twin was envisioned as a tool to save time and costs during process development and optimization. All critical process parameters can be precisely controlled directly at the controller’s touch screen. The device is suitable for microbial and cell culture applications in both glass and single-use bioreactors. The innovative bay-drawer system enables flexible adaptation to unique requirements and changing processes. Frequent updates offered by Eppendorf, such as new functional modules, support for different bioreactor sizes and models, as well as additional software features, will help to enable the SciVario twin to serve your current and future bioprocessing needs.
World Health SummitA total of US$1bn was pledged to the WHO at this year’s World Health Summit in Berlin for the fight against Mpox, Marburg virus and the consequences of climate change.
Ikerian AGSwiss Ikerian AG’s US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside a strategic partnership.
Molcure IncGerman antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery.
Immunic/Nela DornerMultiple sclerosis is currently an incurable, chronic autoimmune disease. While it is possible to effectively manage the feared relapses with existing therapies, novel approaches aim to provide important protection against long-term impairments.
Since 1995, the Eppendorf Award for Young European Investigators, endowed with €20,000, has honored outstanding achievements in the field of biomedical research in Europe once a year.
Stijnstijl fotografieDutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.